Palvella Therapeutics, Inc.
PVLA
$91.67
$0.080.09%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 176.99% | 240.61% | 206.32% | 91.56% | -- |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 184.11% | 247.68% | 122.35% | 19.66% | -- |
| Operating Income | -184.11% | -247.68% | -122.35% | -19.66% | -- |
| Income Before Tax | -567.01% | -358.04% | -200.94% | -167.33% | -- |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -567.01% | -358.04% | -200.94% | -167.33% | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -567.01% | -358.04% | -200.94% | -167.33% | -- |
| EBIT | -184.11% | -247.68% | -122.35% | -19.66% | -- |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 57.15% | -70.16% | -1,038.99% | -1,029.42% | -- |
| Normalized Basic EPS | 59.50% | -18.70% | -591.20% | -1,695.94% | -- |
| EPS Diluted | 57.15% | -70.16% | -1,033.62% | -1,032.68% | -- |
| Normalized Diluted EPS | 59.50% | -18.70% | -573.62% | -1,788.75% | -- |
| Average Basic Shares Outstanding | 300.18% | 132.63% | 35.06% | -28.66% | -- |
| Average Diluted Shares Outstanding | 300.18% | 132.63% | 34.23% | -29.02% | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |